Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quzhu Tongbi Granules is a traditional Chinese medicine (TCM) formulation developed by Zhejiang Chinese Medical University for the treatment of gout. It is specifically designed for patients exhibiting the 'spleen deficiency and dampness obstruction' syndrome (also described as spleen-kidney damp obstruction). The granules are used to manage gout in its intermittent and chronic stages, with research focusing on its ability to reduce gout flares, treat gouty nephropathy, and lower the risk of associated cardiovascular complications. It is typically administered orally and is evaluated both as a standalone therapy and in combination with conventional Western medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quzhu Tongbi Granules.